December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

230.78 -2.96 (-1.27%)
Streaming Delayed Price Updated: 2:04 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera Acquires Foresight Diagnostics
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
News headline image
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
From Natera, Inc.
Via Business Wire
News headline image
Natera Integrates with Flatiron Health’s OncoEMR® Platform
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Third Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Third Quarter Results on November 6, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
From Natera, Inc.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
News headline image
Natera Named to Fast Company’s Next Big Things in Tech List
From Natera, Inc.
Via Business Wire
News headline image
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
From Natera, Inc.
Via Business Wire
News headline image
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
From Natera, Inc.
Via Business Wire
News headline image
Natera Provides Update on Patent Litigation with NeoGenomics
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
From Natera, Inc.
Via Business Wire
News headline image
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Second Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.